DiaGen AI Accelerates Global Drug Discovery with Strategic Board Appointment
New York, Thursday, 12 March 2026.
Today, DiaGen AI appointed healthcare veteran Aditya Tallapragada to its advisory board, accelerating the company’s ambitious push to expand its AI drug discovery platform into the UAE and beyond.
Strategic Expansion and Leadership Restructuring
On March 12, 2026, Vancouver-based DiaGen AI Inc. officially announced the addition of Aditya Tallapragada to its advisory board [1]. Tallapragada, who currently serves as the President of AKT Health Inc., brings over 15 years of specialized experience encompassing healthcare artificial intelligence, clinical research, regulatory affairs, and digital transformation [1]. This strategic appointment is designed to bolster DiaGen AI’s international presence as the company seeks to scale its proprietary drug discovery platform [1].
Bridging Clinical Research and AI Innovation
Tallapragada’s background provides a critical link between theoretical AI models and practical clinical applications [GPT]. He has extensive experience managing Phase II and Phase III oncology clinical trials for pharmaceutical clients throughout East Asia and other international markets [1]. Furthermore, under his leadership, AKT Health established the Decentralized Clinical Trials (DCT) Quarterly Series in Tokyo and Boston, alongside the Global Virtual Healthcare Summit, demonstrating a clear focus on modernizing clinical research methodologies [1].
Future Outlook and Market Penetration
Looking ahead, DiaGen AI has articulated an ambitious corporate strategy that includes executing strategic acquisitions and completing a go-public transaction [1]. A primary geographical focus for this growth is the UAE, building upon the company’s previous recognition in the region [1]. Expressing his enthusiasm for the role, Tallapragada noted his eagerness to contribute to the company’s strategic growth across global healthcare and biotech markets, starting with the Pacific Rim and the UAE, driven by the “caliber of the science” behind DiaGen’s platform [1].